Gastric adenosquamous carcinoma

Summary

Gastric adenosquamous carcinoma (MONDO:0006034) is a cancer with 1 cohort gene (1 CIViC-evidence somatic driver).

At a glance

• Classification: Cancer
• Cohort genes: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric adenosquamous carcinoma
Mondo ID	MONDO:0006034
EFO	EFO:1000029
DOID	DOID:5635
NCIT	C5474
UMLS	C1333761
MedGen	272661
GARD	0024272
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: adenosquamous carcinoma of stomach · adenosquamous carcinoma of the stomach · gastric (stomach) adenosquamous cancer · gastric adenosquamous carcinoma · STAS · stomach adenosquamous carcinoma

Data availability: 6 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › adenosquamous carcinoma › gastric adenosquamous carcinoma

Related subtypes (14): adenosquamous breast carcinoma, esophageal adenosquamous carcinoma, thymic adenosquamous carcinoma, Bartholin gland adenosquamous carcinoma, endometrial adenosquamous carcinoma, adenosquamous prostate carcinoma, adenosquamous lung carcinoma, pancreatic adenosquamous carcinoma, cervical adenosquamous carcinoma, colorectal adenosquamous carcinoma, gallbladder adenosquamous carcinoma, salivary gland adenosquamous carcinoma, liver adenosquamous carcinoma, skin adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
CCNE1			CIViC #11

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CCNE1	HGNC:1589	ENSG00000105173	P24864	G1/S-specific cyclin-E1	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CCNE1	G1/S-specific cyclin-E1	Essential for the control of the cell cycle at the G1/S (start) transition.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CCNE1	Other/Unknown	no		Cyclin_C-dom, Cyclin_N, Cyclin-like_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adrenal tissue	1
oocyte	1
secondary oocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CCNE1	201	ubiquitous	marker	secondary oocyte, oocyte, adrenal tissue

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CCNE1	3,811

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
CCNE1	P24864	22

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 46. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes	1	2855.0×	0.007	CCNE1
PTK6 Regulates Cell Cycle	1	1903.3×	0.007	CCNE1
RHOBTB3 ATPase cycle	1	1142.0×	0.007	CCNE1
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1	878.5×	0.007	CCNE1
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	713.8×	0.007	CCNE1
p53-Dependent G1 DNA Damage Response	1	713.8×	0.007	CCNE1
p53-Dependent G1/S DNA damage checkpoint	1	713.8×	0.007	CCNE1
G1/S DNA Damage Checkpoints	1	671.8×	0.007	CCNE1
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	1	634.4×	0.007	CCNE1
TP53 Regulates Transcription of Cell Cycle Genes	1	543.8×	0.007	CCNE1
Signaling by PTK6	1	543.8×	0.007	CCNE1
Signaling by Non-Receptor Tyrosine Kinases	1	543.8×	0.007	CCNE1
G0 and Early G1	1	439.2×	0.007	CCNE1
Aberrant regulation of mitotic cell cycle due to RB1 defects	1	407.9×	0.007	CCNE1
G1 Phase	1	393.8×	0.007	CCNE1
Diseases of mitotic cell cycle	1	393.8×	0.007	CCNE1
G1/S-Specific Transcription	1	356.9×	0.007	CCNE1
Chaperonin-mediated protein folding	1	300.5×	0.007	CCNE1
Switching of origins to a post-replicative state	1	300.5×	0.007	CCNE1
Synthesis of DNA	1	300.5×	0.007	CCNE1
Association of TriC/CCT with target proteins during biosynthesis	1	292.8×	0.007	CCNE1
Cyclin E associated events during G1/S transition	1	285.5×	0.007	CCNE1
Cyclin A:Cdk2-associated events at S phase entry	1	265.6×	0.007	CCNE1
Protein folding	1	259.6×	0.007	CCNE1
DNA Replication	1	237.9×	0.007	CCNE1
G1/S Transition	1	233.1×	0.007	CCNE1
Cyclin D associated events in G1	1	233.1×	0.007	CCNE1
SCF(Skp2)-mediated degradation of p27/p21	1	207.6×	0.008	CCNE1
Mitotic G1 phase and G1/S transition	1	184.2×	0.008	CCNE1
S Phase	1	181.3×	0.008	CCNE1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of mesenchymal stem cell proliferation	1	2106.5×	0.005	CCNE1
DNA replication initiation	1	624.1×	0.006	CCNE1
homologous chromosome pairing at meiosis	1	601.9×	0.006	CCNE1
positive regulation of G1/S transition of mitotic cell cycle	1	401.2×	0.007	CCNE1
telomere maintenance	1	267.5×	0.008	CCNE1
regulation of protein localization	1	205.5×	0.008	CCNE1
G1/S transition of mitotic cell cycle	1	200.6×	0.008	CCNE1
Wnt signaling pathway	1	99.7×	0.014	CCNE1
protein phosphorylation	1	68.0×	0.018	CCNE1
cell division	1	46.2×	0.024	CCNE1
negative regulation of transcription by RNA polymerase II	1	17.7×	0.056	CCNE1

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CCNE1	PALBOCICLIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CCNE1	38	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PALBOCICLIB	4	CCNE1
ABEMACICLIB	4	CCNE1
GILTERITINIB	4	CCNE1
TRILACICLIB	4	CCNE1
DINACICLIB	3	CCNE1
ALVOCIDIB	3	CCNE1
INDIGO	3	CCNE1
SILMITASERTIB	2	CCNE1
INDIRUBIN	2	CCNE1
SELICICLIB	2	CCNE1
ZOTIRACICLIB	2	CCNE1
NARAZACICLIB	2	CCNE1
CYC-065	2	CCNE1
BMS-919373	2	CCNE1
CROZBACICLIB	2	CCNE1
CT-7001	2	CCNE1
SIMUROSERTIB	2	CCNE1
RONICICLIB	2	CCNE1
EBVACICLIB	2	CCNE1
AT-7519	2	CCNE1
ZEMIRCICLIB	2	CCNE1
CULMERCICLIB	2	CCNE1
TEGTOCICLIB	2	CCNE1
MILCICLIB	2	CCNE1
BMS-754807	2	CCNE1
ASNUCICLIB	2	CCNE1
ISTISOCICLIB	2	CCNE1
PHA-793887	1	CCNE1
SU-9516	1	CCNE1
BMS-387032	1	CCNE1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CCNE1	691	Binding:690, ADMET:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CCNE1	691

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
PALBOCICLIB	4	CCNE1
ABEMACICLIB	4	CCNE1
GILTERITINIB	4	CCNE1
TRILACICLIB	4	CCNE1
DINACICLIB	3	CCNE1
ALVOCIDIB	3	CCNE1
INDIGO	3	CCNE1
SILMITASERTIB	2	CCNE1
INDIRUBIN	2	CCNE1
SELICICLIB	2	CCNE1
ZOTIRACICLIB	2	CCNE1
NARAZACICLIB	2	CCNE1
CYC-065	2	CCNE1
BMS-919373	2	CCNE1
CROZBACICLIB	2	CCNE1
CT-7001	2	CCNE1
SIMUROSERTIB	2	CCNE1
RONICICLIB	2	CCNE1
EBVACICLIB	2	CCNE1
AT-7519	2	CCNE1
ZEMIRCICLIB	2	CCNE1
CULMERCICLIB	2	CCNE1
TEGTOCICLIB	2	CCNE1
MILCICLIB	2	CCNE1
BMS-754807	2	CCNE1
ASNUCICLIB	2	CCNE1
ISTISOCICLIB	2	CCNE1
PHA-793887	1	CCNE1
SU-9516	1	CCNE1
BMS-387032	1	CCNE1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	CCNE1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.